By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – http://careers.regeneron.com


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 





Company News
Regeneron (REGN) Announces Agreement With BARDA For The Manufacturing And Testing Of New Antibodies Against MERS Virus 8/22/2016 6:52:40 AM
Regeneron (REGN) Reports Second Quarter 2016 Financial and Operating Results 8/4/2016 8:16:43 AM
After Bagging $51 Million in Early 2016, Bay Area's Adicet Bio Inks a Five-Year R&D Deal with Regeneron (REGN) 8/2/2016 6:55:20 AM
Sanofi (SNY) And Regeneron (REGN) Announce EMA Acceptance For Review Of Marketing Authorisation Application For Sarilumab 8/1/2016 8:55:03 AM
Regeneron (REGN) Announces Upcoming 2016 Investor Conference Presentation 7/18/2016 6:26:17 AM
Regeneron (REGN) Announces 2016 Winners Of The Regeneron Prize For Creative Innovation 7/13/2016 8:22:05 AM
Regeneron (REGN) Release: Award-Winning Chef Elizabeth Falkner Reveals Her Struggle With Atopic Dermatitis To Highlight The Physical And Psychological Impact Of The Disease 7/12/2016 6:55:28 AM
Regeneron (REGN) To Report Second Quarter 2016 Financial And Operating Results And Host Conference Call And Webcast On August 4, 2016 7/8/2016 7:58:44 AM
Regeneron (REGN) And Sanofi (SNY) Announce Approval Of Praluent (Alirocumab) For The Treatment Of Hypercholesterolemia In Japan 7/5/2016 6:09:41 AM
Drug Companies Need To Tell A Better Story, Regeneron (REGN) Says 6/30/2016 9:41:04 AM
12345678910...
//-->